Table 1 Breakdown of patients treated with FEIBA and FFP according to the initial INR values
Measured parameter | FEIBA | FFP | p value | ||||
|---|---|---|---|---|---|---|---|
INR <5 (n = 51) | INR ≥5 (n = 21) | Total (n = 72) | INR <5 (n = 54) | INR ≥5 (n = 15) | Total (n = 69) | ||
Age | 75(45–90) | 76(51–95) | 75(45–95) | 78(32–91) | 77(36–88) | 77(32–91) | 0.479 |
Sex | 65.3%M | 52.2%M | 61.1%M | 44.4%M | 46.7%M | 44.9%M | 0.079 § |
34.7%F | 47.8%F | 38.9%F | 55.6%F | 53.3%F | 55.1%F | ||
Median INR at admission | 2.6(1.2–4.9) | 12.8(5.0-∞) | 3.3(1.2-∞) | 2.5(1.3–4.8) | 7.4(5-∞) | 2.9(1.3-∞) | 0.104 |
% of patients with INR <5 at admission | 100% | 0% | 70.8% | 100% | 0% | 78.3% | 0.207 |
Median INR after drug administration | 1.4(1.1–3.2) | 1.5(1.1-∞) | 1.5(1.1-∞) | 1.6(1.0–3.2) | 2.0(1.5–4.8) | 1.6(1.0–4.8) | 0.046 |
% of patients with INR ≤1.4 following drug administration | 51.1% | 42.9% | 50.7% | 28.2% | 7.7% | 33.3% | 0.017 § |
Median INR drop | 1.2(-0.1–3.4) | 11.3(0-∞) | 1.8(-0.1-∞) | 0.8(0–3.2) | 11.6(1.2-∞) | 1.0(0-∞) | 0.014 |
Mean hemoglobin at admission (g/dl) | 12.0 ± 3.5 | 9.3 ± 3.3 | 11.1 ± 3.7 | 11.1 ± 2.8 | 10.9 ± 2.6 | 11.1 ± 2.8 | 0.870 |
Dose administered (units) * | 504 ± 19 | 999 ± 40 | 662 ± 234 | 2(1–11) | 4(2–5) | 2(1–11) | n/a |
% of patients with initial 1,000 units FEIBA dose | 0% | 100% | 31.9% | n/a | n/a | n/a | n/a |
% of patients with additional drug dose | 16.3% | 21.2% | 18.1% | 20.4% | 13.3% | 18.8% | 0.923 § |
Median time from drug administration to measurement of INR <1.4 (h) | 2.0(0-∞) | 4.8(0-∞) | 2.0(0-∞) | 23.7(2-∞) | 29.2(12.5–50.9) | 25.2(2-∞) | 0.006 |
% of patients with ICH | 46.9% | 21.7% | 38.9% | 9.3% | 26.7% | 13.0% | <0.001 § |
Median length of hospital stay (days) | 6(1–20) | 6(1–15) | 6(1–20) | 6(1–64) | 5(1–17) | 6(1–64) | 0.521 |
Survival | 79.6% | 73.9% | 77.8% | 88.9% | 85.7% | 88.2% | 0.545 § |